HC Wainwright Comments on Eyenovia FY2029 Earnings

Eyenovia, Inc. (NASDAQ:EYEN) – HC Wainwright issued their FY2029 earnings per share (EPS) estimates for Eyenovia in a note issued to investors on Thursday, February 6th. HC Wainwright analyst M. Caufield forecasts that the company will post earnings of $1.40 per share for the year. HC Wainwright has a “Neutral” rating and a $2.00 price objective on the stock. The consensus estimate for Eyenovia’s current full-year earnings is ($0.52) per share.

A number of other analysts also recently weighed in on EYEN. Brookline Capital Management reiterated a “hold” rating on shares of Eyenovia in a report on Friday, November 15th. William Blair reaffirmed a “market perform” rating on shares of Eyenovia in a research note on Friday, November 15th. Finally, LADENBURG THALM/SH SH reissued a “neutral” rating on shares of Eyenovia in a research note on Monday, November 18th.

Eyenovia Trading Down 11.8 %

NASDAQ EYEN opened at $1.80 on Friday. The firm has a market capitalization of $2.51 million, a PE ratio of -2.47 and a beta of 1.24. The business’s 50-day moving average price is $6.67 and its two-hundred day moving average price is $33.30. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.58. Eyenovia has a 12 month low of $1.80 and a 12 month high of $205.60.

Eyenovia (NASDAQ:EYEN) last posted its earnings results on Tuesday, November 12th. The company reported ($8.80) EPS for the quarter, beating the consensus estimate of ($10.40) by $1.60. Eyenovia had a negative return on equity of 1,108.24% and a negative net margin of 114,639.41%. During the same period in the prior year, the firm earned ($14.40) earnings per share.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Financial Management Network Inc. bought a new stake in shares of Eyenovia during the 3rd quarter valued at $39,000. Nations Financial Group Inc. IA ADV grew its holdings in Eyenovia by 78.6% during the 3rd quarter. Nations Financial Group Inc. IA ADV now owns 90,900 shares of the company’s stock valued at $47,000 after buying an additional 40,000 shares in the last quarter. Finally, Geode Capital Management LLC grew its holdings in Eyenovia by 36.6% during the 3rd quarter. Geode Capital Management LLC now owns 557,994 shares of the company’s stock valued at $288,000 after buying an additional 149,471 shares in the last quarter. Hedge funds and other institutional investors own 25.84% of the company’s stock.

Eyenovia Company Profile

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.